Editorial comment: liver transplantation.
McGuire
Brendan M
BM
Alkurdi
Basem
B
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D006085:Graft Survival; D006509:Hepatitis B / Q000401:mortality / Q000517:prevention & control / Q000601:surgery*; D006526:Hepatitis C / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D012008:Recurrence; D051437:Renal Insufficiency / Q000209:etiology / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab